AA Rubio, VA Baharani, B Dadonaite… - Biorxiv: the Preprint …, 2024 - europepmc.org
The ongoing emergence of SARS-CoV-2 variants of concern (VOCs) that reduce the effectiveness of antibody therapeutics necessitates development of next-generation …
AA Rubio, VA Baharani, B Dadonaite… - … : the preprint server …, 2024 - pubmed.ncbi.nlm.nih.gov
The ongoing emergence of SARS-CoV-2 variants of concern (VOCs) that reduce the effectiveness of antibody therapeutics necessitates development of next-generation …
AA Rubio, VA Baharani, B Dadonaite, M Parada… - bioRxiv, 2024 - biorxiv.org
The ongoing emergence of SARS-CoV-2 variants of concern (VOCs) that reduce the effectiveness of antibody therapeutics necessitates development of next-generation …
AA Rubio, VA Baharani, B Dadonaite… - Biorxiv: the Preprint …, 2024 - europepmc.org
The ongoing emergence of SARS-CoV-2 variants of concern (VOCs) that reduce the effectiveness of antibody therapeutics necessitates development of next-generation …
AA Rubio, VA Baharani, B Dadonaite, M Parada… - bioRxiv, 2024 - biorxiv.org
The ongoing emergence of SARS-CoV-2 variants of concern (VOCs) that reduce the effectiveness of antibody therapeutics necessitates development of next-generation …